Vijaya Diagnostic Centre Limited announced its 24th Annual General Meeting will take place on September 24, 2026. The virtual meeting aims to approve financial results for FY26 and key corporate actions.

The Board recommends a final dividend of ₹2 per equity share for FY26. Shareholders on record as of September 16, 2026, will be eligible for the payout.

Corporate Actions

The agenda includes significant changes to employee compensation structures. The company seeks shareholder approval to increase the Employee Stock Option Pool under the VDCL Employee Stock Option Plan 2018.

This expansion adds 20,00,000 new stock options to the existing pool. The company has already granted 14,62,586 options from the original pool, leaving a residual balance of 1,62,414 options before this increase.

Governance Updates

Mrs. Sura Geeta Reddy retires by rotation and offers herself for re-appointment as a Non-Executive Director. She holds a law degree and serves on the Nomination & Remuneration Committee.

The meeting also seeks ratification for the remuneration of the Cost Auditor, M/s. TSSV Santhosh Kumar. The approved fee is ₹50,000 plus applicable taxes for the financial year ending March 31, 2027.

What the Numbers Show

The proposed ESOP expansion represents a substantial increase in potential equity dilution. By adding 20,00,000 options to the existing 16,25,000 pool, the total authorized options will more than double. This move aligns with the company's network growth from 81 to 162 diagnostic centres over the past five years, suggesting a strategic focus on retaining talent amid operational scale-up.

Vijaya Diagnostic Centre has intimated the stock exchanges that Dr. Manjula Anagani ceased to be an Independent Director on August 21, 2026, following the completion of her tenure.

The departure marks the end of Dr. Anagani’s first term of five years on the board. The company disclosed the change under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Tenure Completion

Dr. Anagani’s role ended at the close of business hours on August 21, 2026. In a letter to the Board of Directors dated May 7, 2026, she confirmed she would not seek re-appointment for a second consecutive five-year term.

She cited pre-occupation and other professional commitments as the reasons for her decision. Dr. Anagani stated there were no other material reasons for her cessation.

Board Appreciation

The company expressed deep appreciation for the valuable services rendered by Dr. Anagani during her tenure. Naga Vasudha Tadepalli, Company Secretary and Compliance Officer, signed the disclosure letter submitted to the National Stock Exchange and BSE Limited.